drugset / Trial / NCT03953599
CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients
Phase 1
Completed
18 enrolled
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19-STAR-T cells in patients with refractory and relapsed B-cell malignancies (such as NHL and ALL ).
Timeline
- Start
- 2019-07-01
- Primary completion
- 2021-07-01
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-STAR-T cells | Cell therapy | — | — |